Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...

Regions face reduced federal research funding and shrinking venture capital for startups, though rankings stay consistent.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...

Aside from the MFN order, President Trump is also in the process of negotiating tariffs with countries all over the world. It ...

To align with global demand and the company's planned maintenance, LYB expects third quarter operating rates of 85% for North ...

TCTC Holdings LLC just sold 7,600 shares of CVS Health Corporation (CVS), dialing down its stake by 2.0%, but still holds a ...

Harvest Fund Management Co. Ltd dramatically reduced its stake in Alibaba Group Holding Limited (BABA) by 47.7% in the first quarter, now holding just 72,057 shares valued at approximately $9.5 ...